Ontology highlight
ABSTRACT:
SUBMITTER: Schwarz KB
PROVIDER: S-EPMC7028138 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
Schwarz Kathleen B KB Rosenthal Philip P Murray Karen F KF Honegger Jonathan R JR Hardikar Winita W Hague Rosie R Mittal Naveen N Massetto Benedetta B Brainard Diana M DM Hsueh Chia-Hsiang CH Shao Jiang J Parhy Bandita B Narkewicz Michael R MR Rao Girish S GS Whitworth Suzanne S Bansal Sanjay S Balistreri William F WF
Hepatology (Baltimore, Md.) 20190819 2
For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct-acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir-sofosbuvir in HCV-infected children aged 3 to <6 years. In an open-label study, patients 3 to <6 years old chronically infected with HCV genotype 1 (n = 33) or 4 (n = 1) received weight-based doses of combined ledipasvir-sofosbuvir as granules (33.75 mg/150 mg for weights ...[more]